BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 12434947)

  • 1. CD25+ immunoregulatory T-cells of donor origin suppress alloreactivity after BMT.
    Johnson BD; Konkol MC; Truitt RL
    Biol Blood Marrow Transplant; 2002; 8(10):525-35. PubMed ID: 12434947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD; Becker EE; LaBelle JL; Truitt RL
    J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions.
    Blazar BR; Lees CJ; Martin PJ; Noelle RJ; Kwon B; Murphy W; Taylor PA
    J Immunol; 2000 Nov; 165(9):4901-9. PubMed ID: 11046015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host disease.
    Xia G; Kovochich M; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2004 Nov; 10(11):748-60. PubMed ID: 15505606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease.
    Johnson BD; Truitt RL
    Blood; 1995 Jun; 85(11):3302-12. PubMed ID: 7756664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Graft-versus-leukemia effect in minor antigen mismatched chimeras given delayed donor leucocyte infusion: immunoregulatory aspects and role of donor T and ASGM1-positive cells.
    Sefrioui H; Billiau AD; Waer M
    Transplantation; 2000 Jul; 70(2):348-53. PubMed ID: 10933162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of graft-versus-host disease by intrabone marrow injection of donor T cells: involvement of bone marrow stromal cells.
    Miyake T; Inaba M; Fukui J; Ueda Y; Hosaka N; Kamiyama Y; Ikehara S
    Clin Exp Immunol; 2008 Apr; 152(1):153-62. PubMed ID: 18307515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of CD25 expression on donor CD8+ and CD4+ T cells with graft-versus-host disease after donor lymphocyte infusions.
    Mutis T; Aarts-Riemens T; Verdonck LF
    Haematologica; 2005 Oct; 90(10):1389-95. PubMed ID: 16219576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
    Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
    Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection.
    Taylor PA; Panoskaltsis-Mortari A; Swedin JM; Lucas PJ; Gress RE; Levine BL; June CH; Serody JS; Blazar BR
    Blood; 2004 Dec; 104(12):3804-12. PubMed ID: 15292057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
    Johnson BD; Becker EE; Truitt RL
    Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early regulation of CD8 T cell alloreactivity by CD4+CD25- T cells in recipients of anti-CD154 antibody and allogeneic BMT is followed by rapid peripheral deletion of donor-reactive CD8+ T cells, precluding a role for sustained regulation.
    Fehr T; Takeuchi Y; Kurtz J; Wekerle T; Sykes M
    Eur J Immunol; 2005 Sep; 35(9):2679-90. PubMed ID: 16082727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
    Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
    J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of graft-versus-host disease by intra-bone marrow injection of donor T cells.
    Fukui J; Inaba M; Ueda Y; Miyake T; Hosaka N; Kwon AH; Sakaguchi Y; Tsuda M; Omae M; Kamiyama Y; Ikehara S
    Stem Cells; 2007 Jun; 25(6):1595-601. PubMed ID: 17446564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B7.2-/- mature dendritic cells generate T-helper 2 and regulatory T donor cells in fetal mice after in utero allogeneic bone marrow transplantation.
    Bhattacharyya S; Cowan MJ
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):657-71. PubMed ID: 16125636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A decrease in graft-vs.-host disease without loss of graft-vs.-leukemia reactivity after MHC-matched bone marrow transplantation by selective depletion of donor NK cells in vivo.
    Johnson BD; Truitt RL
    Transplantation; 1992 Jul; 54(1):104-12. PubMed ID: 1631918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic intrabone marrow-bone marrow transplantation plus donor lymphocyte infusion suppresses growth of colon cancer cells implanted in skin and liver of rats.
    Koike Y; Adachi Y; Suzuki Y; Iwasaki M; Koike-Kiriyama N; Minamino K; Nakano K; Mukaide H; Shigematsu A; Kiyozuka Y; Tubura A; Kamiyama Y; Ikehara S
    Stem Cells; 2007 Feb; 25(2):385-91. PubMed ID: 17284650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.